Compare OPRX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | KRRO |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.0M | 142.0M |
| IPO Year | 2008 | 2019 |
| Metric | OPRX | KRRO |
|---|---|---|
| Price | $8.74 | $8.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $12.60 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 168.6K | 162.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.77 | $56.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.78 | ★ 181.46 |
| 52 Week Low | $4.54 | $5.20 |
| 52 Week High | $22.25 | $46.28 |
| Indicator | OPRX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 34.73 |
| Support Level | $6.92 | $8.29 |
| Resistance Level | $9.13 | $14.32 |
| Average True Range (ATR) | 0.41 | 0.75 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 42.99 | 9.43 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.